Ekso Bionics (NASDAQ:EKSO) CEO Scott Davis Sells 23,315 Shares

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) CEO Scott Davis sold 23,315 shares of the company’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $4.80, for a total value of $111,912.00. Following the completion of the transaction, the chief executive officer directly owned 78,777 shares of the company’s stock, valued at $378,129.60. The trade was a 22.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Ekso Bionics Price Performance

EKSO stock traded up $0.46 during mid-day trading on Wednesday, reaching $5.45. 86,719 shares of the company’s stock were exchanged, compared to its average volume of 117,336. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.66 and a quick ratio of 1.57. Ekso Bionics Holdings, Inc. has a 12-month low of $2.73 and a 12-month high of $14.97. The stock’s 50 day moving average is $4.77 and its 200 day moving average is $16.88. The company has a market cap of $14.30 million, a price-to-earnings ratio of -0.96 and a beta of 1.08.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Tuesday, October 28th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.45. Ekso Bionics had a negative net margin of 70.74% and a negative return on equity of 90.71%. The company had revenue of $4.23 million during the quarter, compared to analyst estimates of $4.16 million. On average, research analysts expect that Ekso Bionics Holdings, Inc. will post -0.48 EPS for the current year.

Institutional Investors Weigh In On Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Armistice Capital LLC lifted its stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 18.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,042,382 shares of the company’s stock after purchasing an additional 316,733 shares during the quarter. Armistice Capital LLC owned about 7.03% of Ekso Bionics worth $823,000 at the end of the most recent reporting period. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ekso Bionics in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Ekso Bionics currently has a consensus rating of “Hold” and a consensus price target of $562.50.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.